Syros to Present on Its Pioneering Approach to Identify Novel Drug Targets Linked to Genomically Defined
Subsets of Patients at IMPAKT Breast Cancer Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to
control the expression of disease-driving genes, today announced that the Company will present data demonstrating the power of its
drug discovery and development platform to identify novel drug targets and associated biomarkers linked to genomically defined
subsets of breast cancer patients through systematic analysis of regulatory regions of the genome. These data will be presented at
the IMPAKT 2017 Breast Cancer Conference taking place from May 4-6 in Brussels, Belgium.
Details on the presentation are as follows:
Date & Time: Thursday, May 4, from 5:30 – 6:30 p.m. CEST
Presentation Title: Epigenomic analysis of primary breast cancer tumors reveals novel tumor cell vulnerabilities and therapeutic
targets
Session Title: Breast cancer target identification, validation and preclinical models
Presenter: Matthew G. Guenther, Principal Scientist, Syros
Poster Number: 47P
Location: SQUARE Brussels Meeting Centre, Delvaux Foyer
About Syros Pharmaceuticals
Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines
that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and
efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically
defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform
has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is
currently focused on cancer and immune-mediated diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead
drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with
acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor with potential in a range of solid
tumors and blood cancers. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located
in Cambridge, Mass.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of
1995, including without limitation statements regarding the clinical utility of Syros’ drug candidates and the benefits of Syros’
gene control platform. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’
‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended
to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results
or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a
result of various important factors, including: Syros’ ability to: advance the development of its programs, including SY-1425 and
SY-1365, under the timelines it projects in current and future clinical trials; demonstrate in any current and future clinical
trials the requisite safety, efficacy and combinability of its drug candidates; replicate scientific and non-clinical data in
clinical trials; successfully develop a companion diagnostic test to identify patients with biomarkers associated with the
RARA super-enhancer; obtain and maintain patent protection for its drug candidates and the freedom to operate under third
party intellectual property; obtain and maintain necessary regulatory approvals; identify, enter into and maintain collaboration
agreements with third parties; manage competition; manage expenses; raise the substantial additional capital needed to achieve its
business objectives; attract and retain qualified personnel; and successfully execute on its business strategies; risks described
under the caption “Risk Factors” in Syros’ Annual Report on Form 10-K for the year ended December 31, 2016, which is on file with
the Securities and Exchange Commission; and risks described in other filings that Syros makes with the Securities and Exchange
Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and
Syros expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future
events or otherwise.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20170427005261r1&sid=mstr1&distro=nx&lang=en)
Media Contact:
Syros Pharmaceuticals
Naomi Aoki, 617-283-4298
naoki@syros.com
or
Investor Contact:
Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200
hannahd@sternir.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170427005261/en/